


# WENGER VIELI AS SWISS LEGAL ADVISOR FOR NLS PHARMACEUTICS

*Posted on 16 December 2022*



**Category:** [Corporate](#)

**Tags:** [Alessa Waibel](#), [andrea christen](#), [Kevin Wilhelm Vangehr](#), [Mark P. Stocker](#), [NLS Pharmaceuticals](#), [Pascal Honold](#), [Slider](#), [wnger vieli](#)



**NLS Pharmaceuticals**, a Swiss clinical-stage biopharmaceutical company, has entered into a definitive agreement with **BVF PARTNERS** to raise aggregate gross proceeds of up to USD 30.0 million in a two-tranche private placement.

The net proceeds will enable the Swiss clinical-stage biopharmaceutical company to advance the ongoing clinical development of its products and further support business development and licensing activities.

**Wenger Vieli** has acted as Swiss legal advisor to NLS Pharmaceuticals on all Swiss legal aspects in connection with the PIPE transaction. The team was led by **Pascal Honold** (partner, m&a/vc/pe) and included **Kevin Wilhelm Vangehr** (associate, m&a/vc/pe), **Alessa Waibel** (associate, financial services), **Andrea Christen** (associate, m&a/vc/pe) and **Mark P. Stocker** (associate, notarial services).